CymitQuimica logo

CAS 1012054-59-9

:

CUDC-101

Description:
CUDC-101 is a small molecule inhibitor that has garnered attention in the field of cancer research due to its ability to target multiple signaling pathways involved in tumor growth and survival. It primarily functions as a dual inhibitor of histone deacetylases (HDACs) and epidermal growth factor receptor (EGFR) signaling, which are crucial in the regulation of gene expression and cell proliferation. The compound is characterized by its ability to induce apoptosis in cancer cells and inhibit tumor growth in various preclinical models. CUDC-101 has shown promise in overcoming resistance to conventional therapies, making it a candidate for combination treatments. Its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion, are essential for determining its efficacy and safety profile in clinical settings. Ongoing research aims to elucidate its full therapeutic potential and optimize its use in targeted cancer therapies. As with any investigational drug, further studies are necessary to fully understand its mechanisms and potential side effects.
Formula:C24H26N4O4
InChI:InChI=1S/C24H26N4O4/c1-3-17-9-8-10-18(13-17)27-24-19-14-22(21(31-2)15-20(19)25-16-26-24)32-12-7-5-4-6-11-23(29)28-30/h1,8-10,13-16,30H,4-7,11-12H2,2H3,(H,28,29)(H,25,26,27)
InChI key:PLIVFNIUGLLCEK-UHFFFAOYSA-N
SMILES:COC1=C(C=C2C(=C1)N=CN=C2NC3=CC=CC(=C3)C#C)OCCCCCCC(=O)NO
Synonyms:
  • Cudc101
  • 7-[[4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl]oxy]-N-hydroxyheptanamide
  • Heptanamide, 7-[[4-[(3-ethynylphenyl)amino]-7-Methoxy-6-quinazolinyl]oxy]-N-hydroxy-
  • 7-[[4-[(3-Ethynylphenyl)amino]-7-Methoxy-6-quinazolinyl]oxy]-N-hydroxyheptanamide
  • 7-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]oxy-N-hydroxyheptanamide
  • CUDC101; CUDC 101; CUDC-101.
  • 7-[[4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl]oxy]-N-hydroxyheptanamide CUDC-101
  • CURIS
  • CS-330
  • CUDC-101
  • See more synonyms
Found 7 products.